Company Overview
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Why Investors Should Care
Trades at a P/E of 21.5, below the sector median of 24.8.
Maintains a net profit margin of 19.5%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.09B (+5.7% YoY); net profit $424.88M.
- Trailing 12 Months Year-on-year growth — revenue +0.3%, earnings +7.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.8%, profit CAGR 0.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.81% |
| 1 Year: | 0.30% |
Compounded Profit Growth
| 5 Years: | 0.13% |
| 1 Year: | 7.90% |
Stock Price Performance
| 1 Year: | -13.14% |
| 6 Months: | -1.31% |
| 3 Months: | +18.03% |
| 1 Month: | +0.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)47.35 · Neutral
P/E of 21.51 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -0.8% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QGEN Qiagen N.V. R3KPHARMA | 42.38 | 21.51 | $8.75B | 0.79% | 9.02% | 11.93% | -0.81% | 0.13% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 483.46M | 533.54M | 532.58M | 540.42M | 492.32M |
| Cost of Revenue | 174.78M | 199.25M | 201.32M | 215.15M | 182.72M |
| Gross Profit | 308.68M | 334.29M | 331.26M | 325.27M | 309.60M |
| Operating Expenses | 183.52M | 198.31M | 193.97M | 203.39M | 192.98M |
| Operating Income | 125.16M | 135.97M | 137.29M | 121.88M | 116.63M |
| EBITDA | 170.75M | 183.90M | 193.91M | 168.70M | 148.09M |
| Interest Expense | 7.29M | 7.61M | 8.22M | 10.14M | 11.05M |
| Pretax Income | 119.55M | 126.82M | 134.73M | 109.17M | 85.83M |
| Tax Provision | 28.79M | 30.57M | 4.68M | 1.34M | 17.79M |
| Net Income | 90.76M | 96.25M | 130.04M | 107.83M | 68.04M |
| Diluted EPS | 0.41 | 0.46 | 0.63 | 0.52 | 0.33 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 2.14B | 1.97B | 1.98B | 2.09B |
| Cost of Revenue | - | 756.96M | 731.62M | 1.01B | 790.50M |
| Gross Profit | - | 1.38B | 1.23B | 967.35M | 1.30B |
| Operating Expenses | - | 808.34M | 788.44M | 767.45M | 779.18M |
| Operating Income | - | 576.23M | 445.25M | 199.90M | 520.31M |
| EBITDA | - | 779.36M | 688.55M | 368.26M | 717.27M |
| Interest Expense | - | 58.36M | 53.41M | 43.84M | 33.26M |
| Pretax Income | - | 512.60M | 429.81M | 121.15M | 490.26M |
| Tax Provision | - | 89.39M | 88.51M | 37.56M | 65.39M |
| Net Income | - | 423.21M | 341.30M | 83.59M | 424.88M |
| Diluted EPS | - | 2.79 | 1.65 | 0.40 | 2.04 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 6.29B | 6.12B | 5.69B | 6.28B |
| Current Assets | - | 2.39B | 2.15B | 1.96B | 2.00B |
| Cash & Equivalents | - | 730.67M | 668.08M | 663.55M | 839.00M |
| Inventory | - | 357.96M | 398.38M | 279.26M | 301.89M |
| Receivables | - | 323.75M | 381.88M | 349.28M | 402.61M |
| Total Liabilities | - | 2.82B | 2.31B | 2.12B | 2.50B |
| Current Liabilities | - | 974.52M | 1.08B | 1.04B | 512.14M |
| Long Term Debt | - | 1.47B | 921.82M | 839.66M | 1.65B |
| Total Debt | - | 1.88B | 1.53B | 1.51B | 1.81B |
| Total Equity | - | 3.47B | 3.81B | 3.57B | 3.78B |
| Shares Outstanding | - | 206.80M | 206.80M | 206.80M | 206.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 715.26M | 459.45M | 673.55M | 654.33M |
| Investing Cash Flow | - | -726.76M | -87.66M | -249.23M | -305.28M |
| Financing Cash Flow | - | -125.80M | -433.83M | -422.90M | -178.98M |
| Capital Expenditure | - | -149.34M | -162.80M | -171.24M | -207.13M |
| Free Cash Flow | - | 565.93M | 296.65M | 502.31M | 447.20M |
| Net Change in Cash | - | -137.30M | -62.03M | 1.43M | 170.07M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 64.7% | 62.8% | 48.9% | 62.2% |
| Operating Margin % | - | 26.9% | 22.7% | 10.1% | 24.9% |
| Net Margin % | - | 19.8% | 17.4% | 4.2% | 20.3% |
| ROE % | - | 12.2% | 9.0% | 2.3% | 11.2% |
| ROCE % | - | 10.8% | 8.8% | 4.3% | 9.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Wellington Management Group, LLP | 6.02% | 12.41M | $537.59M |
| 2 | Price (T.Rowe) Associates Inc | 5.51% | 11.35M | $491.99M |
| 3 | Principal Financial Group, Inc. | 3.23% | 6.65M | $288.09M |
| 4 | Vanguard Capital Management LLC | 3.01% | 6.21M | $269.08M |
| 5 | Blackrock Inc. | 2.87% | 5.91M | $255.89M |
| 6 | Morgan Stanley | 2.45% | 5.04M | $218.49M |
| 7 | Earnest Partners LLC | 2.22% | 4.57M | $198.17M |
| 8 | Goldman Sachs Group Inc | 2.16% | 4.44M | $192.54M |
| 9 | NORGES BANK | 2.10% | 4.33M | $187.41M |
| 10 | Millennium Management Llc | 1.87% | 3.85M | $166.63M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QGEN
Groupe la Francaise Has $3.25 Million Stake in Qiagen N.V. $QGEN - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPQ0RfMHFEYWZkZHNRdkdCNEZJMWJCRXhDRXlySlhPYkljUnhtUnhzZlhKRk1WYjZsbUdIZ3FXOW5oSjdqMENGT1lWdDdZclpBZ1dBNllTOFZXVXdhQk1OVWRVWTJCQWp4WTNtN0Y2WlY1MDl4WFBBWkFUVzBKTnp6b3hmMHhiZGVRdmw0NU…
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOZDB2cXM1VmMxdWczTmFlcE9sYWtIc0JKVHh4SkV1b0ljVXFvNDlmVTI4ZklhSHJDdWdSY1dUb3JCN2VwNEZILWdNb0x1aS1EQ2VWQjVqZmExTlRfREk1aW1tMzBpTjZrSGdxNUl0QWY5cmx2RmJtV3NyZUxrNkJJWi1uTjVuaVM4ejVpVE…
Qiagen N.V. (QGEN) Stock Analysis: Exploring The 5.98% Potential Upside For Investors - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOOFIxME1ranZMbWRFQm5OM2U3UHV3TzQ4VnlkMUpibl9xUko2ejMyb01HTVZYUEZxV1VKcVJzNDA1dG4wRk51eWVaZUhDSldEellRQXk0Y2xVMlAyTjRjREZxN3hRb0xmVzVLY0hQNThRM1dTVXJ4endTZGVwelV3UUstZUxDWktoTHdmcD…
BlackRock Discloses Significant Stake in Qiagen Under AFM Rules - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxPSXdOcU9vb0poV3FfYW5sbWdLc0g4ZGdaOXJhdnZmZ2UyWGZyaUpkMlFZQzcwVUtHWENUbVp0NjBla05iQ0JRZ25lczEwcUpEOVpiLXlWcE5HVXY0dUlMck53SWV6U2l4N0tpNnFsUDhPSUd4d0lQUWd5dThGWF8xbmFyOW9WODJPdmxoSX…
Qiagen’s New QIAsymphony Connect Automation Platform Might Change The Case For Investing In Qiagen (QGEN) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxONml3aGpyV0w2RGFtczRhY1kzTG9OejRJU0tXVXo2ZFkyWmtuanlQRjdZREFpdjN3TzByY08xUHFyOUFjWUotb3psTEg1eUR5aEg0N21KclZsSDZFenc2Vm5mc0dPVVc0RDRwUWN1elJqTV9pSGRyN0o0cXE5aHZpX0hlZHlZbldQNzl0VC…
Liquidity Mapping Around (QGEN) Price Events - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNT0JZRl8yVXY0cFhDVk8tSHFCUGloYV9na2o3cUtLcEE3SEU1NmdrakhBajU1S0pNUVFpUWFEWWduTXdQUHROVldfUlBKQ00zS2FKN1lhanNuSzNnSTVKMmI2NV9WTjQ3WlYyTHFIdmdzV3JrY1JWdEg3a0FjVVV3eTVzV2hyX0haN0tFZk…
QGEN — Frequently Asked Questions
What is the current share price of Qiagen N.V. (QGEN)?
As of 2026-09-19 21:16 PDT, Qiagen N.V. (QGEN) trades at $42.38 on NYSE. Its 52-week range is $32.34 to $55.16.
What is the market capitalisation of QGEN?
Qiagen N.V. (QGEN) has a market capitalisation of $8.75B on NYSE.
What is the P/E ratio of QGEN?
QGEN trades at a trailing price-to-earnings (P/E) ratio of 21.51. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.66.
Does QGEN pay a dividend?
Qiagen N.V. (QGEN) currently offers a dividend yield of 0.79%.
What is the return on equity (ROE) of QGEN?
QGEN has a return on equity (ROE) of 11.93%. Its return on capital employed (ROCE) is 9.02%.
Is QGEN a good stock to buy?
This page provides a data-driven analysis of Qiagen N.V. (QGEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.